An estimate of the total catch in the Spanish Mediterranean Sea and Gulf of Cadiz regions (1950-2010)

The underestimation of fisheries removals is a global issue that spans countries from different continents and different socio-economic situations. Underestimation of catches is especially important in countries where fishing fleets are highly diversified, the enforcement of fishing management is low, data availability is poor, and there is high demand for fish products in local markets. This is the case for Mediterranean countries. Here, we estimated total removals of marine resources by Spain from 1950 to 2010 for the Spanish Mediterranean Sea and Gulf of Cadiz regions following a catch-reconstruction approach. We first collected information from scientific publications, grey literature and secondary sources of information (i.e., personal communications, interviews with managers and fishers) to complement officially reported catch data, which are publicly available from FAO databases and from national and regional statistics. A literature search and fishers interviews provided assessments of missing catch sectors that are time-point estimates. These were used as anchor points of reliable data upon which we then estimated total catch using interpolation to fill in the periods for which quantitative data were missing. Overall, the reconstructed catch was 70% larger than the nationally reported data for the same time period. Results illustrated that unreported removals and discards represent important portions of total removals in the study area. Unreported landings and discards accounted for, on average, 42% of total removals between 1950s and 2010, and were composed of black market sales, subsistence fishing, artisanal fishing, recreational fishing and illegal catch, in addition to discarding. By the late 2000s, recreational fishing was the most important sector for unreported landings (~36%), followed by black market sales (~32%), subsistence fishing (~17%), unreported artisanal fishing (~12%) and illegal catch (~2%). While FAO landings data showed an increase of landings from 1950 to the mid-1960s and a decline from the mid-1970s to 2010, a different trend emerged after accounting for all fisheries removals. Reconstructed total catches revealed an earlier maximum of total removals in the late 1950s, a plateau being reached during the 1960s and 1970s, and a decline from the early 1980s to 2010. Our estimates of total fisheries catches represent an improvement over official catch data, and suggest a different historical trend of marine resource use

Pennella filosa (Linnaeus, 1758) (Copepoda, Siphonostomatoida, Pennellidae) from Coryphaena hippurus Linnaeus, 1758 (Pisces, Coryphaenidae) captured in western Mediterranean (Balearic Islands). Morphological and biological aspects

Abstract: Sixty one fishes of the species Coryphaena hippurus (Linneo, 1758) have been examined for the presence of the pennellid copepod Pennella filosa (Linneo, 1758) from western Mediterranean (Balearic Islands). Prevalence was 46%. Head, neck, genital complex and abdomen were measured as well as horns. The cefalotorax of the parasites were attached in different locations on fishes but mainly on fins and dorsolateral muscles. Mean intensity, mean abundance and range were determined and data has been analysed by means of Pearson Correlation Coefficient. Likewise ecological aspects of the parasitism and some data of biological cycle were examined. Keywords: pennellid, parasitism, prevalence, abundance, ecology. Resumen: Se han examinado sesenta y un especímenes de Coryphaena hippurus (Linneo, 1758) para hallar la presencia del copépodo del género Pennella Pennella filosa (Linneo, 1758) del Mediterráneo occidental (Islas Baleares). La prevalencia fue del 46%. Se realizaron mediciones de cabeza, cuello, complejo genital y abdomen, así como de los “cuernos”. El cefalotórax de los parásitos estaba adherido a diferentes partes del cuerpo de los peces, pero principalmente a las aletas y a los músculos dorsolaterales. Se determinaron la intensidad media, la abundancia media y el rango, y se analizaron los datos mediante el coeficiente de correlación de Pearson. Igualmente, se examinaron aspectos ecológicos del parasitismo y algunos datos del ciclo biológico. Palabras clave: pennella, parasitismo, prevalencia, abundancia, ecología

Randomised, open-label, phase II study of Gemcitabine with and without IMM-101 for advanced pancreatic cancer

Background: Immune Modulation and Gemcitabine Evaluation-1, a randomised, open-label, phase II, first-line, proof of concept study (NCT01303172), explored safety and tolerability of IMM-101 (heat-killed Mycobacterium obuense; NCTC 13365) with gemcitabine (GEM) in advanced pancreatic ductal adenocarcinoma. Methods: Patients were randomised (2 : 1) to IMM-101 (10 mg ml−l intradermally)+GEM (1000 mg m−2 intravenously; n=75), or GEM alone (n=35). Safety was assessed on frequency and incidence of adverse events (AEs). Overall survival (OS), progression-free survival (PFS) and overall response rate (ORR) were collected. Results: IMM-101 was well tolerated with a similar rate of AE and serious adverse event reporting in both groups after allowance for exposure. Median OS in the intent-to-treat population was 6.7 months for IMM-101+GEM v 5.6 months for GEM; while not significant, the hazard ratio (HR) numerically favoured IMM-101+GEM (HR, 0.68 (95% CI, 0.44–1.04, P=0.074). In a pre-defined metastatic subgroup (84%), OS was significantly improved from 4.4 to 7.0 months in favour of IMM-101+GEM (HR, 0.54, 95% CI 0.33–0.87, P=0.01). Conclusions: IMM-101 with GEM was as safe and well tolerated as GEM alone, and there was a suggestion of a beneficial effect on survival in patients with metastatic disease. This warrants further evaluation in an adequately powered confirmatory study

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

BackgroundTreatment of frail patients with advanced colorectal cancer (CRC) is controversial. This pilot phase II trial aimed to assess the efficacy and safety of regorafenib when administered in first-line to frail patients with advanced CRC.MethodsFrail patients without prior advanced colorectal cancer treatment were included in the study. Definition of frailty was defined per protocol based on dependency criteria, presence of chronic comorbid pathologies and/or geriatric features. Main objective: to assess progression-free survival (PFS) rate at 6months. Treatment consisted of 28-daycycles of orally administered regorafenib 160mg/day (3 weeks followed by 1 week rest).ResultsForty-seven patients were included in the study. Median age was 81years (range 63-89). Frailty criteria: dependency was observed in 26 patients (55%), comorbidities in 27 (57%) and geriatric features in 18 (38%). PFS rate at 6months was 45% (95% confidence interval [CI] 30-60]. Median PFS was 5.6months (95%CI 2.7-8.4). Median overall survival (OS) was 16months (95%CI 7.8-24). Complete response, partial response and stable disease were observed in one, two and 21 patients respectively (objective response rate 6.4%; disease control rate 51%). Thirty-nine patients (83%) experienced grade 3-4 adverse events (AEs). The most common grade 3-4 AEs were hypertension (15 patients; 32%), asthenia (14; 30%), hypophosphatemia (6; 13%); diarrhea (4; 8%), hand-foot-skin reaction (4; 8%). There were two toxic deaths (4.2%) (grade 5 rectal bleeding and death not further specified). Dose reduction was required in 26 patients (55%) and dose-delays in 13 patients (28%).ConclusionsThe study did not meet the pre-specified boundary of 55% PFS rate at 6months. Toxicity observed (83% patients experienced grade 3 and 4 AEs) preclude its current use in clinical practice on this setting. Disease control rate and overall survival results are interesting and might warrant further investigation to identify those who benefit from this approach.Trial registrationThis trial was prospectively registered at EudraCT (2013-000236-94). Date of trial registration: April 9th, 2013

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015

Lung cancer is the most common cancer worldwide as well as the leading cause of cancer related deaths as reported by Torre et al (CA Cancer J Clin 65:87–108, 2015]. Non-small cell lung cancer (NSCLC) accounts for up to 85 % of all lung cancers. Multiple advances in the staging, diagnostic procedures, therapeutic options, as well as molecular knowledge have been achieved during the past years, although the overall outlook has not greatly changed for the majority of patients with the overall 5-year survival having marginally increased over the last decade from 15.7 to 17.4 % as reported by Howlader et al.  (SEER Cancer Statistics Review 2015)

LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

Objectives: The aim of LungBEAM was to determine the value of a novel epidermal growth factor receptor (EGFR) mutation test in blood based on BEAMing technology to predict disease progression in advanced non-small cell lung cancer (NSCLC) patients treated with first- or second-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Another goal was to monitor the dynamics of EGFR mutations, as well as to track EGFR exon 20 p.T790M (p.T790M) resistance during treatment, as critical indicators of therapeutic efficacy and patient survival. Methods: Stage IV NSCLC patients with locally confirmed EGFR-TKI sensitizing mutations (ex19del and/or L858R) in biopsy tissue who were candidates to receive first- or second-generation EGFR-TKI as first-line therapy were included. Plasma samples were obtained at baseline and every 4 weeks during treatment until a progression-free survival (PFS) event or until study completion (72-week follow-up). The mutant allele fraction (MAF) was determined for each identified mutation using BEAMing. Results: A total of 68 of the 110 (61.8%) patients experienced a PFS event. Twenty-six patients (23.6%) presented with an emergent p.T790M mutation in plasma at some point during follow-up, preceding radiologic progression with a median of 76 (interquartile ratio: 54–111) days. Disease progression correlated with the appearance of p.T790M in plasma with a hazard ratio (HR) of 1.94 (95% confidence interval [CI], 1.48–2.54; p < 0.001). The HR for progression in patients showing increasing plasma sensitizing mutation levels (positive MAF slope) versus patients showing either decreasing or unchanged plasma mutation levels (negative or null MAF slopes) was 3.85 (95% CI, 2.01–7.36; p < 0.001). Conclusion: Detection and quantification of EGFR mutations in circulating tumor DNA using the highly sensitive BEAMing method should greatly assist in optimizing treatment decisions for advanced NSCLC patients. © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

Introduction: The ROS1 gene rearrangement has become an important biomarker in NSCLC. The College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology testing guidelines support the use of ROS1 immunohistochemistry (IHC) as a screening test, followed by confirmation with fluorescence in situ hybridization (FISH) or a molecular test in all positive results. We have evaluated a novel anti-ROS1 IHC antibody (SP384) in a large multicenter series to obtain real-world data. Methods: A total of 43 ROS1 FISH-positive and 193 ROS1 FISH-negative NSCLC samples were studied. All specimens were screened by using two antibodies (clone D4D6 from Cell Signaling Technology and clone SP384 from Ventana Medical Systems), and the different interpretation criteria were compared with break-apart FISH (Vysis). FISH-positive samples were also analyzed with next-generation sequencing (Oncomine Dx Target Test Panel, Thermo Fisher Scientific). Results: An H-score of 150 or higher or the presence of at least 70% of tumor cells with an intensity of staining of 2+ or higher by the SP384 clone was the optimal cutoff value (both with 93% sensitivity and 100% specificity). The D4D6 clone showed similar results, with an H-score of at least 100 (91% sensitivity and 100% specificity). ROS1 expression in normal lung was more frequent with use of the SP384 clone (p < 0.0001). The ezrin gene (EZR)-ROS1 variant was associated with membranous staining and an isolated green signal FISH pattern (p = 0.001 and p = 0.017, respectively). Conclusions: The new SP384 ROS1 IHC clone showed excellent sensitivity without compromising specificity, so it is another excellent analytical option for the proposed testing algorithm

Floriceps saccatus plerocerci (Trypanorhyncha, Lacistorhynchidae) as parasites of dolphin fish (Coryphaena hippurus L.) and Pompano dolphin (Coryphaena equiselis L.) in Western Mediterranean and Eastern Atlantic Waters. Ecological and biological aspects

A study of the plerocerci of Floriceps saccatus from the abdominal cavity of dolphin fish (Coryphaena hippurus) and pompano dolphin (Coryphaena equiselis) was conducted. In all, 565 dolphin fish es were collected from Majorcan waters (Balearic Islands, western Mediterranean) during 3 summer and autumn seasons (1990, 1991, and 1995). From the Canary Islands (eastern Atlantic), 41 specimens of dolphin fish were caught during 1994 and 49 specimens of pompano dolphin during 1995. Cysts of different shapes and sizes appeared in the conjunctive tissues of the abdomen and viscera, mainly in the liver, gonads, and pancreas. A larva was found inside every cyst examined. Small, medium size, and large larvae were found . The largest larvae correspond to Floriceps saccatus plerocercoids. Stomach contents indicated that crustaceans and fish larvae were the main prey items of juvenile C. hippurus, whereas teleosts and cephalopods were the only food found in adult dolphin fishes. Infection of F. saccatus plerocercoids takes place in preadult dolphin fishes. Prevalence increases as fishes grow and change to a diet of teleosts. Coryphaena equiselis was not infected.103910351,299Q2SCI